112 completed, 70 recruiting, 52 active not recruiting, 28 unknown. 189 Phase 2, 77 Phase 3, 54 Phase 1, 7 Phase 4, 6 Not applicable.
Follow pertuzumab: new trials by email Literature Review of pertuzumab trials Research Report on pertuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer Retifanlimab, Trastuzumab (Herceptin), Pertuzumab - HER2-addicted Breast Cancer | Phase 2 | Not yet recruiting | Polly A. Niravath, MD | 30 | 2026-12-31 | 2026-08-19 |
| Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. Alpelisib, Fulvestrant, Trastuzumab - PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation) | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 51 | 2026-12-15 | 2026-09-18 |
| SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response SHR-A1811, Trastuzumab, Pertuzumab - HER2-positive Breast Cancer, Early Breast Cancer (EBC) | Phase 2 | Not yet recruiting | Fudan University | 358 | 2026-10-01 | 2026-10-02 |
| Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer Fulvestaciclib, Trastuzumab, Pertuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 240 | 2026-10-01 | 2026-07-21 |
| T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 200 | 2026-09-18 | 2026-10-16 |
| Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer Trastuzumab (or biosimilar), Pertuzumab, Culmerciclib - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 31 | 2026-09-01 | 2026-10-19 |
| Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer Culmerciclib, Letrozole, Trastuzumab (TQB211) - Breast Cancer, HR Positive, HER2 Positive Breast Cancer | Phase 2 | Not yet recruiting | Shengjing Hospital | 33 | 2026-09-01 | 2026-08-31 |
| Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study Paclitaxel oral solution plus Trastuzumab and Pertuzumab - HER2 + Breast Cancer | Phase 1 / Phase 2 | Recruiting | Liu Shu | 30 | 2026-07-29 | 2026-08-04 |
| Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer Paclitaxel polymer micelles combined with trastuzumab, pertuzumab, and adrelumab, Taxanes combined with trastuzumab and pertuzumab. - Advanced HER2-positive Breast Cancer | Phase 2 | Recruiting | Fudan University | 140 | 2026-07-28 | 2026-11-02 |
| Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC Docetaxel, Pyrotinib, Trastuzumab (Herceptin) - Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Phase 3 | Recruiting | Shanghai Jiao Tong University School of Medicine | 220 | 2026-07-01 | 2026-09-01 |
| Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer Dalpiciclib, Trastuzumab (Herceptin), Pertuzumab - Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 57 | 2026-06-01 | 2026-05-28 |
| A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer JSKN003, Trastuzumab, Pertuzumab - HER2-positive Recurrent or Metastatic Breast Cancer | Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | 60 | 2026-05-30 | 2026-04-22 |
| Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer olaparib combined with trastuzumab and pertuzumab - Elderly Females, HER2 + Breast Cancer | Phase 4 | Recruiting | Wen-Ming Cao | 45 | 2026-05-25 | 2026-07-10 |
| Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer Fovinaciclib, Aromatase Inhibitors, Trastuzumab + Pertuzumab - HR+/HER2+ Early Breast Cancer | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2026-05-20 | 2026-06-01 |
| Elacestrant in Advanced Triple Positive Breast Cancer Elacestrant, Trastuzumab, Pertuzumab - ER Positive, HER2 Positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | NYU Langone Health | 50 | 2026-05-13 | 2026-05-28 |
| Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging Trastuzumab (Herceptin), Pertuzumab, Combination product: Trastuzumab + Pertuzumab - Breast Cancer | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 156 | 2026-05-01 | 2026-04-17 |
| Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. SHR-A1811, Pertuzumab, trastuzumab - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 100 | 2026-05-01 | 2026-04-14 |
| Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial) Lipo-Dox®, Cyclophosphamide, Trastuzumab (Herceptin) - HER-2 Positive Breast Cancer | Phase 2 | Not yet recruiting | National Taiwan University Hospital | 54 | 2026-04-30 | 2026-05-04 |
| A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer BL-M07D1, Pertuzumab, Trastuzumab - HER2-positive Breast Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 596 | 2026-04-21 | 2026-06-04 |
Showing 20 of 314. Sign in to see all of them.
Breast Neoplasms (198) · Neoplasms (13) · Neoplasm Metastasis (11) · Ovarian Neoplasms (7) · Prostatic Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (6) · Stomach Neoplasms (6) · Brain Neoplasms (5) · Colonic Neoplasms (5) · Inflammatory Breast Neoplasms (5) · Pancreatic Neoplasms (5) · Triple Negative Breast Neoplasms (5) · Colorectal Neoplasms (4) · Endometrial Neoplasms (4) · Hematologic Neoplasms (4)
Hoffmann-La Roche (45) · Genentech, Inc. (17) · Fudan University (8) · National Cancer Institute (NCI) (7) · Dana-Farber Cancer Institute (6) · Second Affiliated Hospital, Zhejiang University, School of Medicine (6) · H. Lee Moffitt Cancer Center and Research Institute (5) · Memorial Sloan Kettering Cancer Center (5) · Shanghai Jiao Tong University School of Medicine (5) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (5) · Henan Cancer Hospital (4) · Shanghai JMT-Bio Inc. (4) · Shengjing Hospital (4) · AstraZeneca (3) · Peking University Cancer Hospital & Institute (3)
United States (126) · China (85) · Spain (56) · Germany (50) · Italy (47) · France (43) · United Kingdom (35) · South Korea (32) · Canada (28) · Belgium (27) · Brazil (26) · Poland (23) · Russia (23) · Mexico (21) · Netherlands (21)
Adrienne Waks, MD (3) · Nancy Lin, MD (3) · Andreas Schneeweiss, MD, Prof. (2) · Chau Dang, MD (2) · Jordan Waypa, FNP (2) · Luca Gianni, MD (2) · Matthew Krebs, Dr (2) · Norman Wolmark, MD (2) · Xuexin He, MD (2) · Zhenzhen Liu (2) · Zhimin Shao, Professor (2)
PMID 28057664, PMID 22149875, PMID 34252375, PMID 12954578, PMID 20124182, PMID 20921468, PMID 21147694, PMID 21376385, PMID 21796368, PMID 22153890, PMID 22198468, PMID 22397650, PMID 22437872, PMID 22623692, PMID 22649152, PMID 22966018, PMID 23602601, PMID 23704196, PMID 23837759, PMID 23868905, PMID 24071851, PMID 24129974, PMID 24457379, PMID 24685829, PMID 24733796, PMID 24919854, PMID 25005255, PMID 25024001, PMID 25109877, PMID 25326492, PMID 25332247, PMID 25524798, PMID 25605862, PMID 25693012, PMID 26342236, PMID 26586415, PMID 26873727, PMID 26979312, PMID 27052654, PMID 27108243, PMID 27179402, PMID 27406346, PMID 27406347, PMID 27486629, PMID 27632289, PMID 27853199, PMID 27955684, PMID 27964843, PMID 28183321, PMID 28314836
2023 (11), 2014 (6), 2017 (5), 2018 (4), 2019 (4), 2009 (3), U10CA180820 (3), U10CA180868 (3), 2015 (2), 2016 (2), 2025 (2), U10CA180888 (2), 2005 (1), 2008 (1), P30CA015083 (1)